Orchard Therapeutics plc (NASDAQ: ORTX) is 50.46% higher on its value in year-to-date trading and has touched a low of $3.76 and a high of $15.93 in the current 52-week trading range. The ORTX stock was last observed hovering at around $6.50 in the last trading session, with the day’s gains setting it 0.36% off its average median price target of $15.00 for the next 12 months. It is also 65.7% off the consensus price target high of $20.00 offered by 9 analysts, but current levels are 23.78% higher than the price target low of $9.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $6.86, the stock is 48.29% and 49.96% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.49 million and changing 5.62% at the moment leaves the stock 9.53% off its SMA200. ORTX registered -51.09% loss for a year compared to 6-month loss of 25.00%. The firm has a 50-day simple moving average (SMA 50) of $4.64 and a 200-day simple moving average (SMA200) of $4.90.
The stock witnessed a 42.23% gain in the last 1 month and extending the period to 3 months gives it a 64.56%, and is 46.07% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.64% over the week and 9.96% over the month.
Orchard Therapeutics plc (ORTX) has around 252 employees, a market worth around $652.99M and $3.20M in sales. Distance from 52-week low is 82.58% and -56.91% from its 52-week high. The company has generated returns on investments over the last 12 months (-52.70%).
Orchard Therapeutics plc (ORTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Orchard Therapeutics plc (ORTX) is a “Buy”. 9 analysts offering their recommendations for the stock have an average rating of 1.60, where 0 rate it as a Hold and 0 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Orchard Therapeutics plc is expected to release its quarterly report on 06/01/2021 and quarterly earnings per share for the current quarter are estimated at -$0.33.The EPS is expected to grow by 34.70% this year, but quarterly earnings will post 17.40% year-over-year.
Orchard Therapeutics plc (ORTX) Top Institutional Holders
99 institutions hold shares in Orchard Therapeutics plc (ORTX), with 221.89k shares held by insiders accounting for 0.23% while institutional investors hold 67.54% of the company’s shares. The shares outstanding are 99.67M, and float is at 81.88M with Short Float at 3.47%. Institutions hold 67.38% of the Float.
The top institutional shareholder in the company is RA Capital Management, L.P. with over 12.32 million shares valued at $50.62 million. The investor’s holdings represent 12.66% of the ORTX Shares outstanding. As of Sep 29, 2020, the second largest holder is FMR, LLC with 12.24 million shares valued at $50.33 million to account for 12.59% of the shares outstanding. The other top investors are Deerfield Management Company, L.P. (Series C) which holds 6.95 million shares representing 7.14% and valued at over $28.56 million, while Artisan Partners Limited Partnership holds 3.75% of the shares totaling 3.65 million with a market value of $15.01 million.
Orchard Therapeutics plc (ORTX) Insider Activity
The most recent transaction is an insider purchase by RA CAPITAL MANAGEMENT, L.P., the company’s 10% Owner. SEC filings show that RA CAPITAL MANAGEMENT, L.P. bought 473,327 shares of the company’s common stock on Sep 24 at a price of $4.61 per share for a total of $2.18 million. Following the purchase, the insider now owns 9.88 million shares.
Orchard Therapeutics plc disclosed in a document filed with the SEC on Aug 21 that RA CAPITAL MANAGEMENT, L.P. (10% Owner) bought a total of 64,642 shares of the company’s common stock. The trade occurred on Aug 21 and was made at $4.62 per share for $0.3 million. Following the transaction, the insider now directly holds 9.41 million shares of the ORTX stock.
Still, SEC filings show that on Aug 20, RA CAPITAL MANAGEMENT, L.P. (10% Owner) acquired 62,631 shares at an average price of $4.61 for $0.29 million. The insider now directly holds 9,342,896 shares of Orchard Therapeutics plc (ORTX).